E
GT Biopharma, Inc. GTBP
$0.61 -$0.15-19.57% NASDAQ
Recommendation
Prev Close
$0.76
Volume
1,946,298
Avg Vol (90D)
1,475,260
Market Cap
$8.04M
Dividend & Yield
--
52-Week Range
$0.54 - $4.10
P/E (TTM)
--
EPS (TTM)
-$3.38
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
11/19/2025 - GuruFocus
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
11/19/2025 - ACCESS Newswire
GT Biopharma price target lowered by $3 at Roth Capital, here's why
11/17/2025 - The Fly
GT Biopharma (NASDAQ:GTBP) Announces Quarterly Earnings Results
11/16/2025 - Ticker Report
GT Biopharma (NASDAQ:GTBP) Posts Earnings Results, Misses Expectations By $0.45 EPS
11/15/2025 - Zolmax
GT Biopharma (GTBP) Reports Q3 Net Loss of $3.1 Million
11/14/2025 - GuruFocus
GT Biopharma reports Q3 results
11/14/2025 - SeekingAlpha.com: All News
GT Biopharma reports Q3 net loss $3.1M vs $3.4M last year
11/14/2025 - TipRanks Financial Blog
GT Biopharma reports Q3 net loss $3.1M vs $3.4M last year
11/14/2025 - The Fly
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/14/2025 - GuruFocus
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/14/2025 - Globe Newswire
Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Increases By 325.7%
10/31/2025 - Ticker Report
GT Biopharma (GTBP) Files for Sale of 14.59 Million Shares
10/24/2025 - GuruFocus
GT Biopharma files to sell 14.59M shares of common stock for holders
10/24/2025 - The Fly
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or ...
10/23/2025 - GuruFocus
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or ...
10/23/2025 - GuruFocus
GT Biopharma provides enrollment update on GTB-3650 Phase 1 trial
10/23/2025 - The Fly
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
10/23/2025 - Globe Newswire
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
10/17/2025 - PR Newswire
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
10/17/2025 - CNW Group - News Releases
Precision Oncology Approaches Drive $312B Market Transformation
10/17/2025 - PR Newswire
Precision Oncology Approaches Drive $312B Market Transformation
10/17/2025 - CNW Group - News Releases
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
10/15/2025 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
10/15/2025 - CNW Group - News Releases
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
10/15/2025 - CNW Group - News Releases
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$10.59M
Net Income (TTM)
-$9.10M
Balance Sheet
Total Assets (Q)
$4.32M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$1.32M
Book Value Per Share (Q)
$0.4955
Cash Flow
Cash from Operations (TTM)
-$11.36M
Cash from Investing (TTM)
$1.00K
Cash from Financing (TTM)
$7.47M
Net Change in Cash (TTM)
-$3.89M
Filings
Filing Date
Friday, November 14, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 16 and 20 (est)
Price History
Loading...
Beta
0.68
7-Day Total Return
-17.18%
30-Day Total Return
-13.06%
60-Day Total Return
-18.68%
90-Day Total Return
-71.05%
Year to Date Total Return
-79.32%
1-Year Total Return
-78.44%
2-Year Total Return
-91.26%
3-Year Total Return
-98.56%
5-Year Total Return
-99.32%
52-week Low
Nov 07, 2025 - $0.54
52-week High
Dec 23, 2024 - $4.10
Valuation
Market Cap
$8.04M - Nano Cap
Enterprise Value
$5.51M
Price/Sales (TTM)
--
Price/Book (Q)
1.53
Dividends and Shares
Shares Outstanding
3.94
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.gtbiopharma.com
Phone Number
415 919 4040
Address
315 Montgomery Street
San Francisco, CA 94104
Country
United States
Year Founded
1965
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed